文献速递细菌感染、耐药与抗菌药物

EUCAST重新定义的药敏分类是否需要调整儿科抗生素剂量?四种常用药物的PBPK模型研究

Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究采用生理药代动力学(PBPK)模型模拟阿莫西林、头孢他啶、头孢呋辛和环丙沙星在成人与儿童中的暴露,比较EUCAST「I」类剂量下AUC与PTA。结果显示儿童按现行剂量暴露随年龄降低而升高,新生儿和婴儿AUC显著高于成人,无需增加儿科剂量,但PTA随年龄和药物-微生物组合差异大。

要点

  • 儿童现行剂量下血浆暴露随年龄降低而增加,新生儿和婴儿AUC显著高于成人EUCAST「I」剂量。
  • 对四种测试药物,无需提高儿科推荐剂量以应对EUCAST「I」类微生物。
  • PTA随年龄和药物-微生物组合变化大,对敏感性降低的微生物可能较差,可个体化调整剂量。

核心结论

  • 与成人不同,测试的四种抗生素无需增加现行儿科推荐剂量来覆盖EUCAST「I」类微生物。

研究设计与样本

  • 使用已有PBPK模型并经成人及儿科药代动力学数据验证,模拟成人EUCAST「I」类剂量和广泛儿科剂量范围,比较AUC及特定药物-微生物组合的PTA。

主要发现

  • 模型验证对所有抗生素均成功。
  • 模拟显示使用现行儿科剂量时,抗生素血浆暴露随年龄降低而增加。
  • 新生儿和婴儿模拟剂量下AUC显著高于接受EUCAST「I」剂量的成人。
  • PTA随年龄高度可变,对敏感性较低的微生物可能较差。

临床怎么用

  • 对阿莫西林、头孢他啶、头孢呋辛和环丙沙星,儿科不应照搬成人EUCAST「I」类的高剂量。
  • 可结合药物-微生物组合和年龄评估PTA,个体化调整儿科剂量。

局限性

  • 研究为基于PBPK模型的模拟,非临床结局研究。
  • 未报告具体AUC数值、PTA阈值或置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: With the redefinition of the EUCAST 'I' susceptibility category, from 'intermediate' to 'susceptible, increased exposure', the focus is now to use higher doses to treat infections of this category. These higher dosages in adults provided by EUCAST are fixed, yet it is uncertain whether a similar increase should apply to paediatric doses. We aimed to compare antibiotic exposure in adults and children, using pragmatic physiologically based pharmacokinetic (PBPK) modelling and simulation to evaluate the need for dose increases in children for the 'I' susceptibility category micro-organisms. METHODS: For amoxicillin, ceftazidime, cefuroxime and ciprofloxacin, we used existing PBPK models and verified them with published adult and paediatric pharmacokinetic data. Then, the adult EUCAST category 'I' doses and a wide paediatric dosage range was simulated. We compared AUC values as a surrogate for antibiotic exposure. In addition, simulations were performed to assess the PTA of the adult and paediatric doses for specific drug-micro-organism combinations. RESULTS: Model verification proved successful for all antibiotics. Simulations showed that antibiotic plasma exposure increases with decreasing age using current paediatric doses. Simulating doses for neonates and infants resulted in substantially higher AUCs compared with adults receiving the EUCAST 'I' dose. Simulations showed that PTA is highly variable with age and can be poor in case of less susceptible micro-organisms. CONCLUSIONS: In contrast to adults, there is no need to increase the currently recommended paediatric dosages for the tested antibiotics. At the same time, further simulations showed that the PTA varies by drug-micro-organism combination and age, providing a potential opportunity to tailor doses to individual patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. de Hoop-Sommen MA, Freriksen JJM, van der Heijden JEM, et al. Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents. J Antimicrob Chemother. 2026. PMID: 41609505. doi:10.1093/jac/dkaf463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。